Bank of New York Mellon Corp Has $187.31 Million Position in Kenvue Inc. $KVUE

Bank of New York Mellon Corp cut its stake in shares of Kenvue Inc. (NYSE:KVUE) by 2.0% during the 1st quarter, HoldingsChannel reports. The firm owned 10,864,537 shares of the company’s stock after selling 223,497 shares during the period. Bank of New York Mellon Corp’s holdings in Kenvue were worth $187,305,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in KVUE. Physician Wealth Advisors Inc. lifted its stake in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the last quarter. Elyxium Wealth LLC bought a new stake in shares of Kenvue during the fourth quarter worth $26,000. MV Capital Management Inc. bought a new stake in shares of Kenvue during the fourth quarter worth $28,000. Reflection Asset Management bought a new stake in shares of Kenvue during the fourth quarter worth $32,000. Finally, SBI Securities Co. Ltd. increased its holdings in shares of Kenvue by 82.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after buying an additional 1,027 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. UBS Group raised their price objective on Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Barclays dropped their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. Citigroup cut their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Finally, Wall Street Zen raised Kenvue to a “buy” rating in a research note on Sunday, July 12th. Three research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $19.50.

Insider Buying and Selling

In related news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.59% of the stock is owned by insiders.

Kenvue Stock Down 0.4%

Shares of NYSE:KVUE opened at $18.94 on Friday. The firm has a market cap of $36.37 billion, a P/E ratio of 22.28, a P/E/G ratio of 1.44 and a beta of 0.47. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $22.87. The business has a fifty day simple moving average of $18.20 and a 200 day simple moving average of $17.85.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.24 EPS. Analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were paid a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s payout ratio is currently 97.65%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.